UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000033113
Receipt number R000037759
Scientific Title RCT of Autism spectrum disorder and probiotics
Date of disclosure of the study information 2018/07/01
Last modified on 2019/10/20 23:04:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

RCT of Autism spectrum disorder and probiotics

Acronym

Autism and probiotics study

Scientific Title

RCT of Autism spectrum disorder and probiotics

Scientific Title:Acronym

Autism and probiotics study

Region

Japan


Condition

Condition

Autism spectrum disorder

Classification by specialty

Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We postulate that children with autism spectrum disorder (ASD) receiving Lactobacillus Reuteri DSM 17938 will make improvements in their behavior and investigate the change of their urine basal oxytocin and microbiota. We will examine the improvements of symptoms associated to change of microbiome and urine basal oxytocin.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Clinical psychiatiric improvement measured by VABS and ABC before and after administration.

Key secondary outcomes

Improvement of gastrointestinal symptoms scores of QPGS-RIII, increasing urine basal Oxytocin and diversity of microbiome and PCA.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Group A (10):L.reuteri DSM 17938 and L.reuteri ATCC PTA 6475 (GASTRUS R)4x108(2Tx2 in a day)for 6 months

Interventions/Control_2

Group B (10): Placebo
6 months

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

6 years-old <=

Age-upper limit

18 years-old >

Gender

Male and Female

Key inclusion criteria

Children diagnosed ASD by neurologist or psychiatrist based on DSM-V with some gastrointestinal symptoms (at least one of IBS symptoms [diarrhea, constipation, and recurrence abdominal pain]).6to18 years old, gender does't matter. Patients who refer to resercher's outpatients clinic during conducting of survey period and get the written request mentioned acknowledgement to informed concent.

Key exclusion criteria

Patients with ASD symptoms due to secondary failure (e.g.cerebral palsy, brain tumor, and neurologic organic disease).

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Megumi
Middle name
Last name Kubota

Organization

Kubota children's clinic

Division name

Pediatrics

Zip code

5440033

Address

2-6-18 Kitakatsuyama Ikunoku Osaka

TEL

06-7894-1100

Email

meg@ki.rim.or.jp


Public contact

Name of contact person

1st name Megumi
Middle name
Last name Kubota

Organization

Kubota children's clinic

Division name

pediatrics

Zip code

5440033

Address

2-6-18 Kitakatsuyama Ikunoku Osaka

TEL

06-7894-1100

Homepage URL

http://www.kubota-kids.com/

Email

meg@ki.rim.or.jp


Sponsor or person

Institute

Kubota children's clinic

Institute

Department

Personal name



Funding Source

Organization

Biogaia AB

Organization

Division

Category of Funding Organization

Outside Japan

Nationality of Funding Organization

Sweden


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Osaka University of Medicine

Address

2-2 Yamadagaoka Suitasi Osaka

Tel

06-6210-8296

Email

rinri@hp-crc.med.osaka-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

くぼたこどもクリニック


Other administrative information

Date of disclosure of the study information

2018 Year 07 Month 01 Day


Related information

URL releasing protocol

http://www.kubota-kids.com/

Publication of results

Unpublished


Result

URL related to results and publications

http://www.kubota-kids.com/

Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2018 Year 06 Month 01 Day

Date of IRB

2018 Year 07 Month 13 Day

Anticipated trial start date

2019 Year 08 Month 01 Day

Last follow-up date

2021 Year 08 Month 01 Day

Date of closure to data entry

2021 Year 08 Month 01 Day

Date trial data considered complete

2021 Year 08 Month 01 Day

Date analysis concluded

2021 Year 08 Month 01 Day


Other

Other related information



Management information

Registered date

2018 Year 06 Month 22 Day

Last modified on

2019 Year 10 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037759


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name